TNXP Tonix Pharmaceuticals Holding Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1430306 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY318.0%
TTM net income YoY-82.4%
TTM EPS YoY-104.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin89.3%
Operating margin-436.3%
Net margin-420.4%
FCF margin-395.0%
EBITDA margin-431.0%
Returns
ROE-84.1%
ROA-73.1%
ROIC (approx.)-387.9%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets17.7%
Debt / equity0.00x
Current ratio4.57x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio-6.3%
Payout ratio—
Capex / revenue11.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $13.11M | $10.09M |
| Cost of revenue | $6.64M | $7.76M |
| Gross profit | $6.47M | $2.33M |
| R&D expense | $44.49M | $39.97M |
| SG&A expense | $87.68M | $40.10M |
| Operating income | -$125.70M | -$136.70M |
| Interest expense | $89,000 | $1.23M |
| Pretax income | -$34.03M | -$80.59M |
| Net income | -$124.02M | -$130.04M |
| EBITDA | -$123.78M | -$133.28M |
| EPS (basic) | -14.57 | -176.60 |
| EPS (diluted) | -14.57 | -176.60 |
| Weighted avg. shares (diluted) | 8.51M | 736,339 |
| Balance sheet | ||
| Cash & equivalents | $207.64M | $99.68M |
| Receivables | $6.27M | $3.68M |
| Inventory | — | $8.41M |
| Current assets | $228.88M | $119.00M |
| PP&E, net | $44.46M | $42.25M |
| Intangibles | $120,000 | $120,000 |
| Total assets | $277.17M | $162.89M |
| Current liabilities | $30.84M | $18.31M |
| Short-term debt | — | $2.82M |
| Long-term debt | — | $4.67M |
| Total debt | — | $7.49M |
| Total liabilities | $32.02M | $23.33M |
| Shareholders' equity | $245.15M | $139.56M |
| Net debt | — | -$92.19M |
| Shares outstanding | 12.79M | 4.39M |
| Cash flow statement | ||
| Operating cash flow | -$99.84M | -$60.92M |
| Capital expenditure | $3.37M | $120,000 |
| Free cash flow | -$103.21M | -$61.05M |
| Investing cash flow | -$4.53M | -$120,000 |
| Financing cash flow | $214.53M | $134.87M |
| Depreciation & amortization | $1.93M | $3.42M |
| Stock-based compensation | $6.02M | $4.78M |
| Share buybacks | $13.76M | — |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.